Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor-specified peripheral niche constraints.

Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor-specified peripheral niche constraints. J Exp Med. 2010 Aug 30; 207(9):1879-89.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.